Wolverine is a vendor-compounded blend of BPC-157 and TB-500 that users take for tissue healing, injury repair, and inflammation and pain management, and community reports skew strongly positive. The most common regimen is 500 mcg a day, with reported doses ranging from 250 mcg to 2 mg, mostly dosed daily. The blend carries no FDA approval, so all human use is off-label or compounded; injection-site reactions and sleep changes each surface only occasionally in community reports, and other common side effects have not been a consistent theme.
Data last updated
Measured on 4 of 6 axes
Evidence shape
Wolverine currently exists as an animal-only research compound, with all available evidence restricted to preclinical and mechanistic studies. There are no published human trials or registered clinical studies for this peptide, meaning its efficacy and safety profile in human subjects remain entirely unverified. Because the existing data is limited to laboratory models, there is no clinical signal to support its use for any specific indication.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 19 out-of-stock offers not shown
Some links are affiliate links. This never affects our rankings or inclusion.
How WOLVERINE is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Most users (≈14 of 31) dose 500 mcg subcutaneously once daily; a smaller group (≈2) dose twice daily, and a few use three‑times‑daily or weekly regimens.